MedTrace Logo

The Influence of FP-10 on the Eradication Rates of H. Pylori by a Triple Therapy

NCT00281047 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 138

Last updated 2006-01-27

No results posted yet for this study

Summary

FP-10 is a food ingredient derived from milk casein. FP-10 can inhibit H. pylori to attach to the gastric epithelium. FP-10 has been made clear to decrease the intragastric urease activity (which is assumed to be produced by H. pylori) measured by the urea breath test. FP-10 can also detach H. pylori from gastric epithelium. We have hypothesized that FP-10 increases the eradication rates by a triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin.

Conditions

  • Helicobacter Pylori

Interventions

DRUG

FP-10

Sponsors & Collaborators

  • Oita University

    collaborator OTHER

  • Hamamatsu University

    lead OTHER

Principal Investigators

  • Takahisa Furuta, MD, PhD · Center for Clinical Research, Hamamatsu University School of Medicine

  • Kazunrai Murakami, MD, PhD · Department of Gastroenterology, Oita University Faculty of Medicine

  • Toshio Fujioka, MD, PhD · Oita University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Completion
2006-05-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00281047 on ClinicalTrials.gov